Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859202 | 0.73 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL19755200 | 0.71 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL16569606 | 0.68 | HRH1 (0.40) | HRH1USP2SMN1; SMN2TDP1PIM1 | |
| SCHEMBL3074674 | 0.68 | CNR2 (0.58) | SMN1; SMN2 | |
| SCHEMBL3084608 | 0.66 | HTR3A (0.51) | — | |
| SCHEMBL3081079 | 0.66 | HTR6 (0.49) | SMN1; SMN2 | |
| SCHEMBL16836629 | 0.64 | LMNA (0.47) | HRH1USP2SMN1; SMN2TDP1 | |
| SCHEMBL6010830 | 0.63 | PTGES (0.50) | — | |
| SCHEMBL4158366 | 0.63 | CHRNB2 (0.42) | — | |
| SCHEMBL6010877 | 0.63 | NCF1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885HRH1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.